Description

Y-shapePEGNHSEster withsuperiorqualityspecificationof ≥95%Substitution.

Y-shapePEGNHS fromJenKemTechnologyisaSuccinimidylCarboxymethylEsterbranched2ARMPEG,reactivetowardstheaminogroupoflysine(s)onproteinsorotherBIOLOGics.AminePEGylationwithY-shapePEGNHScanbecompletedinlessthan1hratpH7-8.JenKemproprietaryY-shapePEGsaremoreselective,duetotheirstericallybulkystructure.PleasereviewtheapplicationnoteforthisproductforadditionalinstructionsforaminePEGylationwithY-NHS-40K.

JenKemTechnologyoffers Y-shapePEGNHS withMW40000,in1gand10gpackingsizes. JenKemTechnology providesrepackagingservicesforanadditionalfee,pleasecontactusifyourequireadifferentpackagesizethanourcatalogselection.

DifferentMWof Y-shapePEGNHS productsmaybeavailablebycustomsynthesis,pleaseemailus attech@jenkemusa.comfordetailsoncustomPEGs.

BulkPEGsandGMPgradePEGsaremade-to-order.Please contactus forbulkpricing.

ApplicationofY-NHS-40KforPEGylation:

DrugMoleculeorOtherEntityPEGylatedwithY-NHS-40K	References
Calciumphosphatenanoparticles	7
Cp40	4
DNAaptamer(SOMAmer)	2
G-CSF	15
Gentamicin	14
IFN-α2a	16
IFN-α2b	17
LIFreceptorantagoNIST(LA)	11
L-RNA(Spiegelmer)	5
L-RNA(Spiegelmer)	8
rhGH	18
TNF-α	9,10

ClickheretodownloadtheMSDS

References:

1.AlQahtani,A.D.,etal.,Productionof“biobetter”glucarpidasevariantstoimprovedrugdetoxificationandantibodydirectedenzymeprodrugtherapyforcancertreatment,EuropeanJournalofPharmaceuticalSciences,2019,127,P.79-91.

2.Haruta,K.,etal.,ANovelPEGylationMethodforImprovingthePharmacokineticPropertiesofAnti-Interleukin-17ARNAAptamers,Nucleicacidtherapeutics,2017,27(1):36-44.

3.Guo,L.,etal.,ApplicationInstructionsforY-NHS-40KforAminePEGylation,click link.

4.Masao,H.,etal.,ChemicallyModifiedInterleukin-6AptamerInhibitsDevelopmentofCollagen-InducedArthritisinCynomolgusMonkeys,NucleicAcidTherapeutics,2015.

5. Winship,A.L.,Interleukin-11altersplacentationandcausespreeclampsiafeaturesinmice,ProcNatlAcadSciUSA.,2015,112(52):15928-33.

6. Risitano,A.M.,etal., PeptideinhibitorsofC3activationasanovelstrategyofcomplementinhibitionforthetreatmentofparoxysmalnocturnalhemoglobinuria, BloodMar,2014,123(13)2094-2101.

7.Roccaro,Aldo M.etal., SDF-1InhibitionTargetstheBoneMarrowNicheforCancerTherapy, CellReports,2014,9(1),p:118–128.

8. Stefan,N.,etal.,NovelProdrug-LikeFusionToxinwithProtease-SensitiveBioorthogonalPEGylationforTumorTargeting,Bioconjugatechemistry, 2014,25.12:2144-2156.

9.Ashokan,A.,etal.,Multifunctionalcalciumphosphatenano-contrastagentforcombinednuclear,magneticandnear-infraredin vivoimaging.Biomaterials,2013,34(29):p.7143-7157.

10.Khan,M.A.,etal., Targetingcomplementcomponent5apromotesvascularintegrityandlimitsairwayremodeling,PNAS,2013,110(15)p:6061-6066.

11. Dai,C.Y., etal.,PreparationandevaluationofanewreleasablePEGylatedtumornecrosisfactor-α(TNF-α)conjugatefortherapeuticapplication,ScienceChinaLifeSciences,2013,56.1:51-58.

12.Dai, C.Y.,etal., LinkagewithcathepsinB-sensitivedipeptidepromotestheinvitroandinvivoanticanceractivityofPEGylatedtumornecrosisfactor-alpha(TNF-α)againstmurinefibrosarcoma, ScienceChinaLifeSci,2011,54(2):128–138.

13. Menkhorst,E.,etal.,VaginallyAdministeredPEGylatedLIFAntagonistBlockedEmbryoImplantationandEliminatedNonTargetEffectsonBoneinMice,PLoSONE, 2011,6(5)e19665.

14. Cai,Y.,etal.,Separationofexenatideanaloguemono-PEGylatedwith40kDApolyethyleneglycolbycationexchangechromatography,JournalofChromatographyA,2011,1218:39,P.6953-6960.

15. Wang,Y-J.,etal.,PEGylationmarkedlyenhancestheinvivopotencyofrecombinanthumannon-glycosylatederythropoietin:Acomparisonwithglycosylatederythropoietin,JournalofControlledRelease, 2010,145:3,p. 306-313.

16.Marcus,Y.,etal.,TurningLow-Molecular-WeightDrugsintoProlongedActingProdrugsbyReversIBLePegylation:AStudywithGentamicin, JournalofMedicinalChemistry,2008,51(14),4300-4305.

17.Wang,S.,etal.,Y-typepolyethyleneglycolmodifiedG-CSFandpreparationmethodandusethereof.PatentCN200780051378,2007.

18.Zhou,W.,etal.,Interferonalpha2amodifiedbypolyethyleneglycol,itssynthesisprocessandapplication.PatentCN200780050541,2007.

19.Zhou,W.,etal.,Interferonalpha2bmodifiedbypolyethyleneglycol,itssynthesisprocessandapplication.PatentCN200780050542,2007.

20.Zhou,W.,etal.,Double-strandedpolyethyleneglycolmodifiedgrowthhormone,preparationmethodandapplicationthereof.PatentCN200880009718,2008.

Foundedin2001byexpertsinPEGsynthesisandPEGylation,JenKemTechnologyspecializesexclusivelyinthedevelopmentandmanufacturingofhighqualitypolyethyleneglycol(PEG)productsandderivatives,andrelatedcustomsynthesisandPEGylationservices.JenKemTechnologyisISO9001andISO13485certified,andadherestoICHQ7AguidelinesforGMPmanufacture.TheproductionofJenKem®PEGsisback-integratedtoin-housepolymerizationfromethyleneoxide,enablingfaciletraceABIlityforregulatedcustomers.JenKemTechnologycaterstothePEGylationneedsofthepharmaceutical,biotechnology,medicaldeviceanddiagnostics,andemergingchemicalspecialtymarkets,fromlaboratoryscalethroughlargecommercialscale.

enKem Technology利用数十年来在创新PEG和单分散PEG衍生物，PEG共聚物和PEG化共轭物的研究，开发和制造方面的专业知识，提供定制PEG合成服务。JenKem Technology已为许多PEG相关技术申请了专利，并尊重他人的知识产权。2020年7月，JenKem Technology获得67项专利批准（中国35项，美国20项，欧洲8项，日本3项，澳大利亚1项），48项待批专利申请（中国22项，美国16项，欧洲5项，1项）印度，巴西1，韩国1、2 PCT），向FDA提交的几种DMF以及正在开发的许多其他创新技术。我们将聘请我们经验丰富的专业技术支持专家来帮助您为您的项目确定正确的高质量PEG。JenKem Technology的研发团队将开发和合成您的PEG或PEG共聚物产品，以在最短的时间内以最高的质量满足您项目的独特需求。通过专用的PEG化服务提供  定制的PEG化缀合物。JenKem Technology还通过定制合成来制造GMP级PEG衍生物和批量订单，从而提供了满足客户特殊质量要求的机会。根据ICH Q7A准则，JenKem Technology能够根据ISO 9001和ISO 13485认证的质量管理体系开发和合成多种GMP PEG衍生物。JenKem Technology可以帮助客户向美国FDA提交DMF，并具有在全球范围内申请专利以保护客户利益的能力。有关JenKem Technology的定制PEG合成服务的详细信息，请通过tech@jenkemusa.com与我们联系。有关我们当前的PEG产品目录的信息，请访问  左侧的PEG产品页面。对于可能有现货的定制产品，请定期访问此链接。JenKem Technology由PEG合成和PEG化的专家成立于2001年，专门研究和生产高质量聚乙二醇（PEG）产品和衍生物，以及相关的定制合成和PEG化服务。JenKem Technology已通过ISO 9001和ISO 13485认证，并遵守ICH Q7A GMP制造准则。JenKem®PEG的生产已从环氧乙烷反向整合到内部聚合中，从而为受监管的客户提供了简便的可追溯性。从实验室规模到大型商业规模，JenKem Technology均可满足制药，生物技术，医疗设备和诊断程序以及新兴化学专业市场的聚乙二醇化需求。